STORM Therapeutics and University of Cambridge win KTP grant
STORM Therapeutics, the Cambridge drug discovery company focused on the discovery of small molecule therapies modulating RNA epigenetics, and The University of Cambridge have been granted a Knowledge Transfer Partnership (KTP).
The grant, of up to £240,000, is to develop an analysis platform using the data warehouse software InterMine to help STORM advance its cancer research.
STORM has established a pipeline of drug discovery programmes to develop novel, first-in-class drugs for the treatment of specific cancers and other diseases with high unmet medical need.
Chief executive Keith Blundy said: “Biology is an extremely fast paced, changing area. STORM is on the cutting edge of cancer research and keeping up with the data that is constantly being generated is vital.
“Previously, this data has been spread across a number of silos and gathering all of this information, as well as being able to analyse it efficiently, can be costly and prone to error.
“Through the KTP programme STORM is now partnered with an open-source data warehouse, InterMine, specifically for the integration and analysis of complex biological data, making it easy to query and analyse.”
Gos Micklem, principal investigator for the InterMine project based at the Department of Genetics at the University of Cambridge added: “We are excited by this KTP award and the opportunity to collaborate with STORM.
“We see benefits on both sides – STORM gains our experience in large-scale data integration and the freely available open-source InterMine platform, while the adaptations that will be made to accommodate their data and interests will improve InterMine for the benefit of the broader community.”
The KTP programme helps businesses in the UK by linking them with an academic organisation, enabling them to bring in new skills and the latest academic thinking to deliver a specific, strategic innovation project.
• PHOTOGRAPH SHOWS: Keith Blundy